Clinical Trials

Phase 1 Enrolling by invitation

Prostatic Neoplasms, Castration-Resistant

NCT06788509 2026-04-13

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

120 enrolled

GenitourinaryLymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Prostatic Neoplasms, Castration-Resistant

NCT06242470 2026-02-05

A Study of MGC026 in Participants With Advanced Solid Tumors

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

250 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Prostatic Neoplasms, Castration-Resistant

NCT06067841 2026-02-04

A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

140 enrolled

Neoplasms, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT05519449 2026-01-20

ENGAGER-PSMA-01

272 enrolled

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT04428788 2025-12-22

Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer

131 enrolled

Neoplasms, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT05252390 2025-11-06

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

BreastGastrointestinalGenitourinaryGynecologic

82 enrolled

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Triple Negative Breast Neoplasms

NCT05293496 2025-10-14

A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

DermatologicGastrointestinalGenitourinaryGynecologic

31 enrolled

Carcinoma, Ovarian Epithelial, Carcinoma, Renal Cell, Liver Neoplasms, Melanoma, Carcinoma, Pancreatic Ductal, Prostatic Neoplasms, Castration-Resistant

NCT02204072 2025-07-15

BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)

120 enrolled 28 charts

Prostatic Neoplasms, Castration-Resistant

NCT04597411 2025-03-21

Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer

99 enrolled

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT04249947 2025-02-17

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

40 enrolled

GenitourinaryHead & Neck

Carcinoma, Adenoid Cystic, Genital Neoplasms, Male, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Salivary Gland Neoplasms, Urogenital Neoplasms, Carcinoma, Acinar Cell, Carcinoma, Mucoepidermoid, Prostatic Neoplasms, Castration-Resistant

NCT02625857 2025-02-03

Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer

26 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT04404140 2023-10-17

A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).

6 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT04541225 2023-07-14

Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors

74 enrolled

BreastCNSGenitourinary

Breast Neoplasms, Glioblastoma, Glioma, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT03551782 2022-02-25

A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer

33 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT02162836 2020-04-27

A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer

6 enrolled